Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  •  (2)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

FDA Panel Rules Against NeurogesX Patch for HIV-Related Neuropathy

February 15, 2012

A Food and Drug Administration panel of outside experts has ruled against using a product derived from chili peppers to treat neuropathic pain in people with HIV. The committee voted 12-0 that clinical data do not show substantial evidence that NeurogesX Inc.'s Qutenza is effective against pain in the extremities suffered by many HIV patients. The experts also voted 11-0, with one abstention, that the capsaicin patch's risk-benefit profile was not acceptable for use by persons with HIV.

Back to other news for February 2012

Adapted from:
Reuters
02.09.2012; David Morgan


  
  • Email Email
  • Comments Comments
  •  (2)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
FDA Pain Patch Decision: Making a "Sophie's Choice" With People's Lives (on HIVandHepatitis.com)
Neurological Complications of AIDS Fact Sheet
Neuropathy Treatment & HIV/AIDS

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement